These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 11162793)

  • 1. Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses.
    García-Sastre A
    Virology; 2001 Jan; 279(2):375-84. PubMed ID: 11162793
    [No Abstract]   [Full Text] [Related]  

  • 2. Binding of the influenza A virus NS1 protein to PKR mediates the inhibition of its activation by either PACT or double-stranded RNA.
    Li S; Min JY; Krug RM; Sen GC
    Virology; 2006 May; 349(1):13-21. PubMed ID: 16466763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virology. Clues to the virulence of H5N1 viruses in humans.
    Krug RM
    Science; 2006 Mar; 311(5767):1562-3. PubMed ID: 16543447
    [No Abstract]   [Full Text] [Related]  

  • 4. Sabotage of antiviral signaling and effectors by influenza viruses.
    Wolff T; Zielecki F; Abt M; Voss D; Semmler I; Matthaei M
    Biol Chem; 2008 Oct; 389(10):1299-305. PubMed ID: 18713015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. To Conquer the Host, Influenza Virus Is Packing It In: Interferon-Antagonistic Strategies beyond NS1.
    Weber-Gerlach M; Weber F
    J Virol; 2016 Oct; 90(19):8389-94. PubMed ID: 27440898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferon-regulated factor 3-mediated antiviral response.
    Horscroft N; Bellows D; Ansari I; Lai VC; Dempsey S; Liang D; Donis R; Zhong W; Hong Z
    J Virol; 2005 Mar; 79(5):2788-96. PubMed ID: 15708997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paramyxovirus strategies for evading the interferon response.
    Gotoh B; Komatsu T; Takeuchi K; Yokoo J
    Rev Med Virol; 2002; 12(6):337-57. PubMed ID: 12410527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biophysical characterization of the complex between double-stranded RNA and the N-terminal domain of the NS1 protein from influenza A virus: evidence for a novel RNA-binding mode.
    Chien CY; Xu Y; Xiao R; Aramini JM; Sahasrabudhe PV; Krug RM; Montelione GT
    Biochemistry; 2004 Feb; 43(7):1950-62. PubMed ID: 14967035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.
    Hartman AL; Towner JS; Nichol ST
    Virology; 2004 Oct; 328(2):177-84. PubMed ID: 15464838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses.
    López CB; García-Sastre A; Williams BR; Moran TM
    J Infect Dis; 2003 Apr; 187(7):1126-36. PubMed ID: 12660927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory Nonstructural Proteins of Influenza A Viruses.
    Klemm C; Boergeling Y; Ludwig S; Ehrhardt C
    Trends Microbiol; 2018 Jul; 26(7):624-636. PubMed ID: 29373257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and functional characterization of two infectious salmon anaemia virus (ISAV) proteins with type I interferon antagonizing activity.
    García-Rosado E; Markussen T; Kileng O; Baekkevold ES; Robertsen B; Mjaaland S; Rimstad E
    Virus Res; 2008 May; 133(2):228-38. PubMed ID: 18304672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of viral antagonists of type I interferon in negative-strand RNA viruses.
    García-Sastre A
    Curr Top Microbiol Immunol; 2004; 283():249-80. PubMed ID: 15298172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral proteins that bind double-stranded RNA: countermeasures against host antiviral responses.
    Krug RM
    J Interferon Cytokine Res; 2014 Jun; 34(6):464-8. PubMed ID: 24905203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in the ability of human influenza A viruses to induce and inhibit the IFN-beta pathway.
    Hayman A; Comely S; Lackenby A; Murphy S; McCauley J; Goodbourn S; Barclay W
    Virology; 2006 Mar; 347(1):52-64. PubMed ID: 16378631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of nonsegmented negative-strand RNA virus replication by siRNA.
    Barik S
    Virus Res; 2004 Jun; 102(1):27-35. PubMed ID: 15068877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interfering vaccine: a novel antiviral that converts a potentially virulent infection into one that is subclinical and immunizing.
    Noble S; McLain L; Dimmock NJ
    Vaccine; 2004 Aug; 22(23-24):3018-25. PubMed ID: 15297051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The N- and C-terminal domains of the NS1 protein of influenza B virus can independently inhibit IRF-3 and beta interferon promoter activation.
    Donelan NR; Dauber B; Wang X; Basler CF; Wolff T; García-Sastre A
    J Virol; 2004 Nov; 78(21):11574-82. PubMed ID: 15479798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A site on the influenza A virus NS1 protein mediates both inhibition of PKR activation and temporal regulation of viral RNA synthesis.
    Min JY; Li S; Sen GC; Krug RM
    Virology; 2007 Jun; 363(1):236-43. PubMed ID: 17320139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-induced Mx proteins in antiviral host defense.
    Haller O; Staeheli P; Kochs G
    Biochimie; 2007; 89(6-7):812-8. PubMed ID: 17570575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.